Essex Woodlands Healthcare Partners

VitalConnect specializes in developing wearable biosensor technology for continuous patient monitoring. The company designs adhesive patches that adhere to the body, enabling the real-time recording of vital signs. By integrating expertise in biomedical engineering, data analytics, and chip design, VitalConnect's products support healthcare professionals in various settings, including hospitals and post-discharge care. The data collected can be easily accessed via mobile devices or computer systems, allowing for immediate response to urgent situations and providing valuable insights into patient health. This technology aims to enhance decision-making processes in clinical environments and improve overall patient care.

Boiron is a prominent manufacturer of homeopathic medicines, known for its commitment to high manufacturing standards and adherence to Food and Drug Administration regulations, as well as the Homeopathic Pharmacopoeia. The company offers a diverse range of products, which are primarily divided into nonproprietary medicines and over-the-counter specialties. Nonproprietary medicines are generic and do not reference specific therapeutic indications, while the specialties include popular first-resort remedies available in various formats such as tablets, drops, syrups, and ointments. Boiron's product lineup features well-known items like Oscillococcinum, Stodal, and Arnigel. The company operates across multiple regions, with a significant portion of its revenue generated in France, alongside markets in Europe and North America. Additionally, Boiron has developed a mobile application for iOS users, further enhancing its engagement with consumers.

VitalConnect specializes in developing wearable biosensor technology for continuous patient monitoring. The company designs adhesive patches that adhere to the body, enabling the real-time recording of vital signs. By integrating expertise in biomedical engineering, data analytics, and chip design, VitalConnect's products support healthcare professionals in various settings, including hospitals and post-discharge care. The data collected can be easily accessed via mobile devices or computer systems, allowing for immediate response to urgent situations and providing valuable insights into patient health. This technology aims to enhance decision-making processes in clinical environments and improve overall patient care.

Enercon Technologies is an electronics manufacturing company that provides product development, testing, marketing, and design services.

TELA Bio, Inc. is a medical technology company based in Malvern, Pennsylvania, established in 2012. The company specializes in the design, development, and marketing of tissue reinforcement materials aimed at addressing unmet needs in soft tissue reconstruction. TELA Bio offers a range of products, including the OviTex Reinforced Tissue Matrix, which is utilized in hernia repair and abdominal wall reconstruction, and the OviTex PRS Reinforced Tissue Matrix, designed for plastic and reconstructive surgery. Additionally, TELA Bio provides OviTex products specifically for laparoscopic and robotic-assisted surgical procedures, which are derived from ovine rumen and incorporate polypropylene fiber. The company's marketing efforts are primarily focused in the United States, utilizing a direct sales force to promote its innovative solutions in soft tissue repair.

Venus Concept Inc. is a medical aesthetic technology company based in Toronto, Canada, specializing in the development and commercialization of minimally invasive and non-invasive devices and treatments. Its diverse product portfolio includes platforms such as Venus Versa, a multi-treatment solution for aesthetic procedures; Venus Legacy, designed for complex face and body needs; and Venus Viva, a customizable skin resurfacing device. The company also offers solutions for hair restoration, including NeoGraft and ARTAS robotic systems, which facilitate follicle harvesting and implantation. Other products address skin tightening, fat reduction, and vaginal health restoration. Venus Concept is recognized for its innovative approach and commitment to enhancing patient experiences within the medical aesthetics sector, generating a significant portion of its revenue from the United States.

Grundium specializes in the development of portable digital microscope scanners aimed at enhancing the field of digital pathology. By utilizing cutting-edge mobile technology, the company enables high-quality professional diagnoses applicable to humans, animals, plants, and more. Its innovative products facilitate live telepathology consultations between surgeons and pathologists, allowing for the scanning and digitization of high-resolution images directly from operating rooms and research centers. This approach not only improves the accessibility and quality of diagnostic pathology but also significantly reduces time and costs associated with traditional methods.

VitalConnect specializes in developing wearable biosensor technology for continuous patient monitoring. The company designs adhesive patches that adhere to the body, enabling the real-time recording of vital signs. By integrating expertise in biomedical engineering, data analytics, and chip design, VitalConnect's products support healthcare professionals in various settings, including hospitals and post-discharge care. The data collected can be easily accessed via mobile devices or computer systems, allowing for immediate response to urgent situations and providing valuable insights into patient health. This technology aims to enhance decision-making processes in clinical environments and improve overall patient care.

Laboratoires Majorelle is a French independent pharmaceutical company focused on addressing public health concerns, particularly in the field of sexual health. Established with the goal of improving access to essential medicines, the company specializes in offering contraception and treatments for sexually transmitted diseases, erectile disorders, and urinary incontinence. By prioritizing responsible practices, Laboratoires Majorelle aims to provide effective health solutions for both men and women in France, ensuring that critical health needs are met.

COTA, Inc. is a Boston-based company that specializes in developing a platform designed to provide data and insights related to cancer patients, aimed at guiding treatment decisions. Founded in 2011 by a team of doctors, engineers, and data scientists, COTA utilizes proprietary technology and advanced analytics to transform fragmented electronic health record (EHR) data into cohesive, research-grade information. This platform supports oncology practices and cancer centers by identifying variations in care, thus enabling the design of effective treatment programs and payment models. COTA's solutions serve a diverse range of stakeholders, including healthcare providers, payers, life sciences companies, and the FDA, ultimately striving to enhance patient outcomes and reduce healthcare costs associated with cancer care.

Metabolon, Inc. is a health technology company specializing in metabolomics, focusing on the development of diagnostic tests and analytical methods for early disease detection and precision medicine. The company offers a range of clinical diagnostics, including QUANTOSE IR for measuring insulin resistance, QUANTOSE IGT for assessing glucose tolerance, and Meta IMD for identifying metabolites linked to inherited metabolic disorders. In addition to its diagnostic capabilities, Metabolon provides customizable research services and multiomics solutions to support academic and commercial investigations across various life science sectors. Its technologies are applicable in areas such as cardiovascular health, diabetes, oncology, and respiratory disorders. Founded in 2000 and headquartered in Morrisville, North Carolina, with additional offices in Europe and sales locations in the UK, Spain, and China, Metabolon collaborates with numerous strategic partners in the pharmaceutical and biotechnology industries to enhance research and development outcomes.

Metabolon, Inc. is a health technology company specializing in metabolomics, focusing on the development of diagnostic tests and analytical methods for early disease detection and precision medicine. The company offers a range of clinical diagnostics, including QUANTOSE IR for measuring insulin resistance, QUANTOSE IGT for assessing glucose tolerance, and Meta IMD for identifying metabolites linked to inherited metabolic disorders. In addition to its diagnostic capabilities, Metabolon provides customizable research services and multiomics solutions to support academic and commercial investigations across various life science sectors. Its technologies are applicable in areas such as cardiovascular health, diabetes, oncology, and respiratory disorders. Founded in 2000 and headquartered in Morrisville, North Carolina, with additional offices in Europe and sales locations in the UK, Spain, and China, Metabolon collaborates with numerous strategic partners in the pharmaceutical and biotechnology industries to enhance research and development outcomes.

Cardiva Medical, Inc. is a medical device company that specializes in vascular access management products designed to facilitate the body's healing process after catheterization procedures. The company offers several innovative products, including the VASCADE VCS, an extravascular and bioabsorbable femoral access closure system that promotes rapid hemostasis while reducing complications. Additionally, Cardiva Medical provides the Cardiva CATALYST, a manual compression assistance device that enhances coagulation for patients requiring temporary hemostasis. Another key product is the VASCADE MVP, which is used for multi-site venous closure during electrophysiology procedures, such as cardiac ablation. Founded in 2002 and headquartered in Santa Clara, California, Cardiva Medical serves physicians and cardiac centers throughout the United States, focusing on transforming vascular closure practices to improve patient outcomes.

MiMedx Group, Inc. is a biopharmaceutical company based in Marietta, Georgia, focused on developing and marketing regenerative biologics derived from human placental tissue allografts. Utilizing its proprietary PURION Process, the company employs aseptic processing techniques and terminal sterilization to create a range of allografts. Key products include EpiFix, a membrane designed for chronic wound treatment, and AmnioFix, which is used in surgical procedures. Other offerings consist of AmnioCord and EpiCord, dehydrated human umbilical cord allografts, and AmnioFill, a connective tissue matrix. MiMedx's products cater to various healthcare sectors, including wound care, burns, surgical applications, orthopedics, sports medicine, ophthalmics, and dentistry. The company distributes its products through a direct sales force, independent agents, and third-party representatives.

Cognate BioServices, Inc. is a contract bioservices organization based in Memphis, Tennessee, specializing in the development and manufacturing of cell and cell-mediated gene therapy products for biotechnology companies and institutions across the United States. Established in 2002 and formerly known as Cognate Therapeutics, the company offers a comprehensive range of services, including process development, regulatory compliance, assay development, preclinical support, stem cell services, cell banking, and characterization. Cognate is known for its expertise in both adherent and non-adherent cell systems, as well as advanced cryopreservation techniques. With a team of highly experienced professionals and cGMP facilities, Cognate BioServices is positioned as a leading contract manufacturer in the field of cell-based products, bolstered by a strategic partnership with Akron Biotechnology, LLC.

Sonendo, Inc. is a medical technology company based in Laguna Hills, California, specializing in innovative solutions for root canal therapy. Founded in 2006, the company has developed the GentleWave System, a technology platform that enhances the cleaning and disinfection of tooth structures without compromising integrity. This system significantly improves clinical outcomes and practice efficiency compared to traditional root canal methods. In addition to its product offerings, Sonendo is the parent company of TDO Software, which provides widely used practice management software for endodontic professionals. The software integrates various functionalities, including imaging and communication tools, to streamline practice workflows. Through its focus on advanced dental technologies, Sonendo aims to address the global challenge of tooth decay, ultimately promoting better dental health.

Venus Concept Inc. is a medical aesthetic technology company based in Toronto, Canada, specializing in the development and commercialization of minimally invasive and non-invasive devices and treatments. Its diverse product portfolio includes platforms such as Venus Versa, a multi-treatment solution for aesthetic procedures; Venus Legacy, designed for complex face and body needs; and Venus Viva, a customizable skin resurfacing device. The company also offers solutions for hair restoration, including NeoGraft and ARTAS robotic systems, which facilitate follicle harvesting and implantation. Other products address skin tightening, fat reduction, and vaginal health restoration. Venus Concept is recognized for its innovative approach and commitment to enhancing patient experiences within the medical aesthetics sector, generating a significant portion of its revenue from the United States.

Cognate BioServices, Inc. is a contract bioservices organization based in Memphis, Tennessee, specializing in the development and manufacturing of cell and cell-mediated gene therapy products for biotechnology companies and institutions across the United States. Established in 2002 and formerly known as Cognate Therapeutics, the company offers a comprehensive range of services, including process development, regulatory compliance, assay development, preclinical support, stem cell services, cell banking, and characterization. Cognate is known for its expertise in both adherent and non-adherent cell systems, as well as advanced cryopreservation techniques. With a team of highly experienced professionals and cGMP facilities, Cognate BioServices is positioned as a leading contract manufacturer in the field of cell-based products, bolstered by a strategic partnership with Akron Biotechnology, LLC.

BioTissue is a technology company focused on developing medical solutions using human amniotic and umbilical cord tissues. Founded in 2001 and based in Miami, Florida, the company offers a platform that processes placental tissue to maintain its biological and structural integrity. This innovative approach provides healthcare professionals with products that possess anti-inflammatory, anti-scarring, and anti-angiogenesis properties, enhancing regenerative healing in various medical fields such as eye care, wound care, and orthopedics. By addressing unmet clinical needs, BioTissue aims to improve patient healing outcomes through its advanced regenerative medicine solutions.

Encore Dermatology is a privately held, fully-integrated dermatology company based in Malvern, Pennsylvania, established in 2015. The company specializes in delivering prescription therapies and medical devices to dermatologists, focusing on a variety of medical dermatology products. These offerings address several topical disease states, including conditions like acne and atopic dermatitis, thereby facilitating enhanced skincare and treatment options for patients. Through its comprehensive approach, Encore Dermatology aims to improve patient outcomes and streamline the dermatological care process.

EyePoint Pharmaceuticals, Inc. is a specialty biopharmaceutical company focused on developing and commercializing ophthalmic products for the treatment of eye diseases in the United States and Europe. The company offers several FDA-approved products, including ILUVIEN for diabetic macular edema, YUTIQ for chronic non-infectious uveitis, DEXYCU for post-operative ocular inflammation, and Retisert for posterior segment uveitis. Additionally, EyePoint is advancing its pipeline with innovative therapies such as EYP-1901, targeting wet age-related macular degeneration and diabetic retinopathy, and YUTIQ50 for uveitis. The company employs its proprietary Durasert and Verisome technology platforms to create sustained-release drug delivery systems that provide controlled drug delivery over extended periods. EyePoint has established strategic collaborations with various organizations to enhance its product offerings and has a commercial alliance for the joint promotion of DEXYCU. Founded in 1987 and headquartered in Watertown, Massachusetts, EyePoint was formerly known as pSivida Corp. and rebranded in March 2018.

COTA, Inc. is a Boston-based company that specializes in developing a platform designed to provide data and insights related to cancer patients, aimed at guiding treatment decisions. Founded in 2011 by a team of doctors, engineers, and data scientists, COTA utilizes proprietary technology and advanced analytics to transform fragmented electronic health record (EHR) data into cohesive, research-grade information. This platform supports oncology practices and cancer centers by identifying variations in care, thus enabling the design of effective treatment programs and payment models. COTA's solutions serve a diverse range of stakeholders, including healthcare providers, payers, life sciences companies, and the FDA, ultimately striving to enhance patient outcomes and reduce healthcare costs associated with cancer care.

Venus Concept Inc. is a medical aesthetic technology company based in Toronto, Canada, specializing in the development and commercialization of minimally invasive and non-invasive devices and treatments. Its diverse product portfolio includes platforms such as Venus Versa, a multi-treatment solution for aesthetic procedures; Venus Legacy, designed for complex face and body needs; and Venus Viva, a customizable skin resurfacing device. The company also offers solutions for hair restoration, including NeoGraft and ARTAS robotic systems, which facilitate follicle harvesting and implantation. Other products address skin tightening, fat reduction, and vaginal health restoration. Venus Concept is recognized for its innovative approach and commitment to enhancing patient experiences within the medical aesthetics sector, generating a significant portion of its revenue from the United States.

Xenex is a company focused on reducing healthcare-associated infections (HAIs) through its advanced ultraviolet disinfection technology. Founded in 2009 and based in San Antonio, Texas, Xenex has developed a portable device that utilizes pulsed xenon UV light to eliminate harmful microorganisms in hospital environments. Since launching its disinfection system in June 2010, the company’s devices have been integrated into infection control protocols in nearly three hundred hospitals across the United States. By effectively reducing the bacterial load that contributes to HAIs, Xenex aims to enhance patient safety and safeguard healthcare staff, ultimately striving to save lives and alleviate suffering in healthcare settings.

Prolacta Bioscience Inc. is a life science company dedicated to improving the health of premature and critically ill infants in neonatal intensive care units (NICUs) through the development of standardized human milk-based nutritional products. Founded in 1999 and headquartered in Duarte, California, Prolacta specializes in creating unique formulations exclusively made from human milk, including human milk fortifiers, caloric fortifiers, and ready-to-feed formulas. Notably, it is the only company that offers a human milk fortifier composed entirely of 100% human milk, known as Prolact+ H2MF. The company operates a pharmaceutical-grade processing facility that employs patented methods to ensure the safety and quality of its products. Prolacta Bioscience is committed to advancing the science of human milk and making a significant impact on the lives of vulnerable infants through innovative research and specialized nutritional solutions.

Metabolon, Inc. is a health technology company specializing in metabolomics, focusing on the development of diagnostic tests and analytical methods for early disease detection and precision medicine. The company offers a range of clinical diagnostics, including QUANTOSE IR for measuring insulin resistance, QUANTOSE IGT for assessing glucose tolerance, and Meta IMD for identifying metabolites linked to inherited metabolic disorders. In addition to its diagnostic capabilities, Metabolon provides customizable research services and multiomics solutions to support academic and commercial investigations across various life science sectors. Its technologies are applicable in areas such as cardiovascular health, diabetes, oncology, and respiratory disorders. Founded in 2000 and headquartered in Morrisville, North Carolina, with additional offices in Europe and sales locations in the UK, Spain, and China, Metabolon collaborates with numerous strategic partners in the pharmaceutical and biotechnology industries to enhance research and development outcomes.

Suneva Medical, Inc. is an aesthetics company based in San Diego, California, specializing in the development, manufacturing, and commercialization of innovative products for the dermatology, plastic, and cosmetic surgery markets. The company is best known for Bellafill, a unique dermal filler that is distinguished by its five-year safety and efficacy data and its approval for the correction of facial acne scars. In addition to Bellafill, Suneva Medical offers Puregraft, a fat grafting solution that enhances long-term graft retention, as well as a platform for processing platelet-rich plasma to optimize patient outcomes. The company is dedicated to delivering differentiated aesthetic products that provide high satisfaction for both patients and healthcare providers, thereby creating significant business opportunities for its partners. Suneva Medical was founded in 2008 and has an additional office in Santa Barbara, California.

TearScience, Inc. is a medical device company based in Morrisville, North Carolina, focused on the identification, diagnosis, and treatment of Meibomian Gland Dysfunction (MGD), which is the primary cause of evaporative dry eye affecting over 100 million people globally. The company has developed innovative devices such as the LipiFlow Activator, which delivers automated therapeutic energies to meibomian glands while safeguarding the eye's delicate structures, and LipiScan, an imaging system that allows eye care professionals to assess gland health. MGD is often under-recognized and contributes significantly to dry eye symptoms such as irritation, dryness, and visual disturbances. By providing a comprehensive in-office system, TearScience enables eye care professionals to effectively address the root causes of evaporative dry eye, ultimately improving patient outcomes. The company, originally known as Kolis Scientific, Inc., was rebranded in 2005 and is now a subsidiary of Johnson & Johnson Surgical Vision, Inc.

Kona Medical, Inc. is a medical technology company founded in 2009 and based in Issaquah, Washington. It specializes in the development of a non-invasive ultrasound-based therapy system aimed at treating hypertension, particularly in patients with drug-resistant hypertension. The company's flagship product, Surround Sound, utilizes ultrasound imaging to precisely guide the application of focused ultrasound energy for renal denervation, targeting the nerves connected to the kidneys to help regulate blood pressure. By offering a less invasive alternative to traditional treatments, Kona Medical seeks to address the health risks associated with high blood pressure while improving patient outcomes through advanced therapeutic techniques.

QSpex Technologies, Inc. is an optical service center based in Alpharetta, Georgia, that specializes in producing high-quality finished eyewear in the United States. Founded in 2007, the company developed a patented method for manufacturing premium lenses directly in optical offices, allowing for a cost-effective and efficient process. Utilizing advanced touchless transfer technology, QSpex enables the quick fabrication of lenses, including single vision, progressive, anti-reflective, photochromic, and polar options, with lens treatments integrated during the production process. This innovative approach allows eyewear providers to deliver finished products to patients on the same day as their eye exams. However, the company filed for voluntary liquidation under Chapter 7 in June 2020.

Revance Therapeutics is a biotechnology company that focuses on developing, manufacturing, and commercializing neuromodulators for aesthetic and therapeutic applications. Its primary product, DaxibotulinumtoxinA for injection (DAXI), is undergoing various clinical trials for treating conditions such as glabellar lines, cervical dystonia, adult upper limb spasticity, and plantar fasciitis, while also being explored for chronic migraine treatment. Additionally, Revance is developing topical formulations of DAXI and a biosimilar to BOTOX. The company has established collaborations for the development and commercialization of these products. Revance also offers a portfolio of aesthetic products, including the RHA Collection of dermal fillers and the HintMD platform. Founded in 1999 and headquartered in Newark, California, Revance Therapeutics was previously known as Essentia Biosystems.

Catalyst Biosciences, Inc. is a clinical-stage biopharmaceutical company headquartered in South San Francisco, California. The company specializes in developing innovative treatments for hemophilia and other rare bleeding disorders, utilizing its engineered subcutaneous coagulation factors to promote blood clotting. This approach aims to address the inherent limitations of traditional intravenous treatments and improve patient outcomes. Catalyst's product portfolio includes Marzeptacog alfa (activated), an advanced coagulation Factor VIIa that has completed Phase II development for hemophilia A or B with inhibitors, and Dalcinonacog alfa, a next-generation Factor IX therapy that has finished Phase IIb clinical trials for hemophilia B. Additionally, the company is working on CB 2679d-GT, an early-stage gene therapy for hemophilia B, as well as other treatments targeting dry age-related macular degeneration and systemic complement inhibitors. Catalyst Biosciences has also formed strategic collaborations with Mosaic Biosciences and Biogen to enhance its research and development efforts in these therapeutic areas. The company was founded in 2002 and has a commitment to addressing unmet medical needs in coagulation and complement disorders.

Yantai Beacon Medical Technology Co., Ltd., founded in 2012 and headquartered in Yantai, China, specializes in the manufacture of medical equipment, notably medical gas systems and oxygen supply systems. The company also offers purification engineering services. Originally established in 1999 as Yantai Beacon Group Company Limited, it operates as a subsidiary of Bright Future (Hong Kong) Holding Ltd. Through its innovative solutions, Yantai Beacon Medical aims to enhance healthcare delivery by providing essential medical technologies.

Kona Medical, Inc. is a medical technology company founded in 2009 and based in Issaquah, Washington. It specializes in the development of a non-invasive ultrasound-based therapy system aimed at treating hypertension, particularly in patients with drug-resistant hypertension. The company's flagship product, Surround Sound, utilizes ultrasound imaging to precisely guide the application of focused ultrasound energy for renal denervation, targeting the nerves connected to the kidneys to help regulate blood pressure. By offering a less invasive alternative to traditional treatments, Kona Medical seeks to address the health risks associated with high blood pressure while improving patient outcomes through advanced therapeutic techniques.

BreatheAmerica operates outpatient clinics that specialize in treating patients with chronic airway diseases, including allergies, asthma, and sinusitis. Founded in 2006 in Nashville, Tennessee, by Joseph C. Hutts and Derril Reeves, the company focuses on enhancing healthcare delivery for individuals suffering from these conditions. BreatheAmerica's treatment centers aim to identify the root causes of symptoms and develop personalized treatment plans, allowing patients to initiate their care more swiftly and improving the likelihood of successful outcomes. The company is committed to improving patient experiences while also striving to reduce overall healthcare costs.

Catalyst Biosciences, Inc. is a clinical-stage biopharmaceutical company headquartered in South San Francisco, California. The company specializes in developing innovative treatments for hemophilia and other rare bleeding disorders, utilizing its engineered subcutaneous coagulation factors to promote blood clotting. This approach aims to address the inherent limitations of traditional intravenous treatments and improve patient outcomes. Catalyst's product portfolio includes Marzeptacog alfa (activated), an advanced coagulation Factor VIIa that has completed Phase II development for hemophilia A or B with inhibitors, and Dalcinonacog alfa, a next-generation Factor IX therapy that has finished Phase IIb clinical trials for hemophilia B. Additionally, the company is working on CB 2679d-GT, an early-stage gene therapy for hemophilia B, as well as other treatments targeting dry age-related macular degeneration and systemic complement inhibitors. Catalyst Biosciences has also formed strategic collaborations with Mosaic Biosciences and Biogen to enhance its research and development efforts in these therapeutic areas. The company was founded in 2002 and has a commitment to addressing unmet medical needs in coagulation and complement disorders.

QSpex Technologies, Inc. is an optical service center based in Alpharetta, Georgia, that specializes in producing high-quality finished eyewear in the United States. Founded in 2007, the company developed a patented method for manufacturing premium lenses directly in optical offices, allowing for a cost-effective and efficient process. Utilizing advanced touchless transfer technology, QSpex enables the quick fabrication of lenses, including single vision, progressive, anti-reflective, photochromic, and polar options, with lens treatments integrated during the production process. This innovative approach allows eyewear providers to deliver finished products to patients on the same day as their eye exams. However, the company filed for voluntary liquidation under Chapter 7 in June 2020.

Kona Medical, Inc. is a medical technology company founded in 2009 and based in Issaquah, Washington. It specializes in the development of a non-invasive ultrasound-based therapy system aimed at treating hypertension, particularly in patients with drug-resistant hypertension. The company's flagship product, Surround Sound, utilizes ultrasound imaging to precisely guide the application of focused ultrasound energy for renal denervation, targeting the nerves connected to the kidneys to help regulate blood pressure. By offering a less invasive alternative to traditional treatments, Kona Medical seeks to address the health risks associated with high blood pressure while improving patient outcomes through advanced therapeutic techniques.

NeoVista Inc is focused on developing medical technologies aimed at improving the treatment of wet age-related macular degeneration (AMD), a condition that affects over 5 million people globally and is a leading cause of blindness among individuals over the age of 50. The company is engaged in clinical studies to validate its innovative technology, which shows promise in enhancing patient care and alleviating the challenges posed by this debilitating condition for both patients and healthcare providers. Through its efforts, NeoVista aims to significantly impact the quality of life for those affected by wet AMD.

Abiomed is a company that specializes in mechanical circulatory support devices aimed at assisting heart failure patients. It develops, manufactures, and markets products designed to improve blood flow and temporarily aid the heart's pumping function, allowing the organ to rest, heal, and recover. Its devices are primarily utilized in cardiac catheterization labs by interventional cardiologists and in surgical settings by heart surgeons. These products are essential for patients requiring hemodynamic support before, during, or after procedures such as angioplasty and heart surgery. A significant portion of Abiomed's revenue is generated from its Impella product portfolio, which includes advanced percutaneous micro heart pumps equipped with integration motors and sensors.

IntegenX, Inc. specializes in developing human DNA identification solutions, particularly for forensics and law enforcement. The company utilizes advanced technology platforms that combine fluidics, optics, and biochemistry to create automated sample-to-answer products for DNA-based identity testing. Among its offerings are the RapidHIT System, which automates the production of standardized DNA profiles from various human samples, and the RapidHIT GlobalFiler Express Kit, designed for direct processing of crime scene samples. Additionally, IntegenX provides systems like the Apollo 100 and Apollo 200 for DNA sequencing and sample preparation. Founded in 2003 and based in Pleasanton, California, IntegenX was previously known as Microchip Biotechnologies, Inc. and became a subsidiary of Thermo Fisher Scientific Inc. in 2018. The company's products are distributed internationally across various countries, enhancing their reach in the market for reliable DNA identification solutions.

Grupo Biotoscana is a biopharmaceutical company based in Latin America, formed through the merger of two established specialty pharmaceutical firms with over 25 years of experience each. The company focuses on developing, manufacturing, and selling pharmaceutical products aimed at addressing unmet medical needs, particularly in oncology, hematology, severe infectious diseases, and rare genetic disorders. Grupo Biotoscana is recognized for its expertise in complex therapeutic areas and maintains long-term collaborations with prominent global pharmaceutical companies, enhancing its ability to deliver specialized treatments and innovative solutions in the healthcare sector.

BreatheAmerica operates outpatient clinics that specialize in treating patients with chronic airway diseases, including allergies, asthma, and sinusitis. Founded in 2006 in Nashville, Tennessee, by Joseph C. Hutts and Derril Reeves, the company focuses on enhancing healthcare delivery for individuals suffering from these conditions. BreatheAmerica's treatment centers aim to identify the root causes of symptoms and develop personalized treatment plans, allowing patients to initiate their care more swiftly and improving the likelihood of successful outcomes. The company is committed to improving patient experiences while also striving to reduce overall healthcare costs.

Entellus Medical, operating as Stryker ENT, specializes in developing innovative solutions for the minimally invasive treatment of chronic sinusitis, eustachian tube dysfunction, and nasal airway obstruction. The company offers a range of products, including the XprESS ENT dilation system and the customizable XprESS LoProfile for balloon dilation procedures. Their portfolio also features the LATERA absorbable nasal implant, which supports cartilage structures, as well as various surgical instruments and imaging solutions tailored for ear, nose, and throat specialists. By focusing on less invasive techniques, Entellus Medical aims to improve patient outcomes, reduce recovery times, and minimize complications such as pain and bleeding. The company's approach includes the FinESS Sinus Treatment, which remodels sinus passages using a micro endoscope and balloon catheter, allowing for procedures that can be performed under local anesthesia. Founded in 2006 and based in Plymouth, Minnesota, Entellus Medical operates as a subsidiary of Stryker Corporation, emphasizing collaboration with healthcare professionals to address unmet needs in the ENT field.

Revance Therapeutics is a biotechnology company that focuses on developing, manufacturing, and commercializing neuromodulators for aesthetic and therapeutic applications. Its primary product, DaxibotulinumtoxinA for injection (DAXI), is undergoing various clinical trials for treating conditions such as glabellar lines, cervical dystonia, adult upper limb spasticity, and plantar fasciitis, while also being explored for chronic migraine treatment. Additionally, Revance is developing topical formulations of DAXI and a biosimilar to BOTOX. The company has established collaborations for the development and commercialization of these products. Revance also offers a portfolio of aesthetic products, including the RHA Collection of dermal fillers and the HintMD platform. Founded in 1999 and headquartered in Newark, California, Revance Therapeutics was previously known as Essentia Biosystems.

NeoVista Inc is focused on developing medical technologies aimed at improving the treatment of wet age-related macular degeneration (AMD), a condition that affects over 5 million people globally and is a leading cause of blindness among individuals over the age of 50. The company is engaged in clinical studies to validate its innovative technology, which shows promise in enhancing patient care and alleviating the challenges posed by this debilitating condition for both patients and healthcare providers. Through its efforts, NeoVista aims to significantly impact the quality of life for those affected by wet AMD.

Symphogen specializes in the development of recombinant polyclonal antibodies (rpAb), a novel class of biopharmaceuticals aimed at treating and preventing serious human diseases, including infectious diseases and cancer. The company has created compositions of recombinant polyclonal antibodies for specific medical applications, such as the treatment of idiopathic thrombocytopenic purpura and the prevention of hemolytic disease in newborns. These innovations help mitigate adverse reactions from smallpox vaccinations and facilitate quicker treatment initiation for cancer patients, ultimately improving the chances of successful outcomes.

Endologix, Inc. is a medical device company that specializes in developing, manufacturing, marketing, and selling innovative solutions for the treatment of abdominal aortic aneurysms (AAA) both in the United States and internationally. The company offers a range of minimally invasive endovascular aneurysm repair (EVAR) products, including the AFX Endovascular AAA System, VELA Proximal Endograft, and Ovation abdominal stent graft system. Additionally, Endologix provides an endovascular aneurysm sealing (EVAS) system designed to seal aneurysms while maintaining blood flow to the legs. Their product offerings also include various extensions and accessories to tailor treatments to individual patient anatomies. Founded in 1992 and headquartered in Irvine, California, Endologix has a direct sales force as well as a network of third-party distributors and agents to market its products. The company was previously known as Radiance Medical Systems, Inc. until its name change in May 2002.

ProteinSimple is a prominent company within the Protein Platforms division of Bio-Techne, specializing in innovative solutions for protein analysis. The company develops a comprehensive range of tools designed to assist life science researchers in addressing complex protein analysis challenges, thereby facilitating insights into proteins and their roles in diseases. Its product offerings include advanced immunoassay systems for quantifying protein expression and sophisticated systems for assessing the structure and purity of protein-based therapeutics. Additionally, ProteinSimple provides nano-proteomic analysis systems that enable researchers to measure phospho-protein signaling and activation in small biological samples, allowing for the quantification of phospho-protein isoforms in various cell types. Through these capabilities, ProteinSimple supports critical research in understanding cellular processes and monitoring drug actions in diverse biological contexts.

Accumetrics is a privately-held company based in San Diego, California, that specializes in the development, manufacturing, and marketing of the VerifyNow System, which includes a comprehensive suite of assays for assessing platelet function. Founded in 1996, the company initially sold to Radiometer in 2000 but was repurchased by its management and investors in 2003. Accumetrics focuses on diagnostic instrumentation and test kits designed to measure individual responses to various antiplatelet agents, providing essential tools for healthcare professionals in the evaluation of platelet activity and ensuring effective patient treatment.

Healthcare Brands International (HBI) is a new company helping to turn innovative medical product technology into successful consumer brands.

EUSA Pharma, founded in March 2006 and headquartered in the UK, is a profitable specialty pharmaceutical company that operates globally with a focus on oncology and other critical diseases. The company markets a portfolio of five approved specialty hospital products, including Caphosol®, Xenazine®, Collatamp®, Custodiol®, and Fomepizole®, along with several named-patient products. EUSA Pharma is dedicated to addressing rare diseases and conditions such as oral mucositis, a common side effect of cancer treatments. The company has submitted a Marketing Authorization Application for FOTIVDA (tivozanib HCL) as a first-line therapy for renal cell carcinoma. With plans to expand its portfolio through acquisitions and in-licensing, EUSA Pharma's operations extend across Europe and the USA, supported by a network of commercial partners in Europe, the Middle East, Asia, and Latin America, making its products available in approximately 40 countries worldwide. The company is led by an experienced management team with a strong track record in the specialty pharmaceutical sector.

MedAvante, Inc. specializes in technology-enabled signal detection solutions for clinical trials targeting central nervous system disorders on a global scale. The company offers various services, including the Virgil Investigative Study Platform for site-based assessments and MedAvante Central Ratings, which facilitates live assessments conducted by remote clinicians. Additionally, MedAvante provides scientific risk reduction services such as rater qualification and training, central review for monitoring assessments, and remote ratings to mitigate bias and variability in trial results. Founded in 2002 and based in Hamilton, New Jersey, MedAvante has established a reputation for delivering standardized and expert central raters who conduct live interviews with trial participants via videoconferencing or telephone, contributing to successful outcomes in numerous global trials. MedAvante operates as a subsidiary of WIRB - Copernicus Group, Inc.

Complete Genomics specializes in high-quality, affordable DNA sequencing and analysis, facilitating large-scale research into the genetic mechanisms of drug responses and complex diseases. The company has developed a comprehensive genomics analysis platform that integrates proprietary human sequencing technology with advanced informatics and data management software. This approach ensures that customers receive ready-to-use data for genome-based research, supporting advancements in personalized medicine and broader genetic studies. By combining innovative technology with a unique market strategy, Complete Genomics aims to transform the landscape of DNA sequencing.

TearScience, Inc. is a medical device company based in Morrisville, North Carolina, focused on the identification, diagnosis, and treatment of Meibomian Gland Dysfunction (MGD), which is the primary cause of evaporative dry eye affecting over 100 million people globally. The company has developed innovative devices such as the LipiFlow Activator, which delivers automated therapeutic energies to meibomian glands while safeguarding the eye's delicate structures, and LipiScan, an imaging system that allows eye care professionals to assess gland health. MGD is often under-recognized and contributes significantly to dry eye symptoms such as irritation, dryness, and visual disturbances. By providing a comprehensive in-office system, TearScience enables eye care professionals to effectively address the root causes of evaporative dry eye, ultimately improving patient outcomes. The company, originally known as Kolis Scientific, Inc., was rebranded in 2005 and is now a subsidiary of Johnson & Johnson Surgical Vision, Inc.

White Pine Medical, Inc. is a private equity firm specializing in late stage investing. The firm seeks to invest in medical device companies. The company was founded in 2010 and is based in Park City, Utah.

ikaSystems Corporation is a provider of cloud-based enterprise resource planning technology tailored for the healthcare sector, particularly serving health insurers in their commercial, Medicare, and Medicaid operations. Founded in 1999 and headquartered in Southborough, Massachusetts, the company offers a comprehensive suite of solutions designed to streamline business processes and enhance operational efficiency. Key offerings include member, provider, and employer portals that facilitate administrative self-service and automate various processes such as claims submission and eligibility verification. Additionally, ikaSystems provides robust tools for claims administration, premium billing, and data warehousing, as well as applications aimed at improving care management and quality assurance. Their technology supports healthcare payers in navigating complex sales, marketing, and regulatory requirements, ultimately enabling clients to improve their business efficiency across various sectors, including telecommunications and financial services.

Velcera is a specialty pharmaceutical company with a passion for assuring pets receive the medicines they need to support excellent overall health. At Velcera, they are dedicated to developing innovative, high-quality products for the pet health market. They comply with the highest standards of practice through all phases, from development to manufacturing to marketing.

Revance Therapeutics is a biotechnology company that focuses on developing, manufacturing, and commercializing neuromodulators for aesthetic and therapeutic applications. Its primary product, DaxibotulinumtoxinA for injection (DAXI), is undergoing various clinical trials for treating conditions such as glabellar lines, cervical dystonia, adult upper limb spasticity, and plantar fasciitis, while also being explored for chronic migraine treatment. Additionally, Revance is developing topical formulations of DAXI and a biosimilar to BOTOX. The company has established collaborations for the development and commercialization of these products. Revance also offers a portfolio of aesthetic products, including the RHA Collection of dermal fillers and the HintMD platform. Founded in 1999 and headquartered in Newark, California, Revance Therapeutics was previously known as Essentia Biosystems.

Molecular Partners is a clinical-stage biopharmaceutical company focused on developing innovative therapies for serious diseases, with a primary emphasis on oncology. The company specializes in a unique class of protein therapeutics known as DARPin® therapeutics, which are engineered to be potent, specific, and versatile. Molecular Partners has an extensive product pipeline that is organized into three main areas: ophthalmology, targeting retinal diseases such as wet age-related macular degeneration and diabetic macular edema; oncology, featuring DARPin candidates with novel mechanisms of action, including multi-DARPin compounds; and additional therapeutic areas. Through its research and development efforts, Molecular Partners aims to significantly enhance disease management and patient outcomes.

Entellus Medical, operating as Stryker ENT, specializes in developing innovative solutions for the minimally invasive treatment of chronic sinusitis, eustachian tube dysfunction, and nasal airway obstruction. The company offers a range of products, including the XprESS ENT dilation system and the customizable XprESS LoProfile for balloon dilation procedures. Their portfolio also features the LATERA absorbable nasal implant, which supports cartilage structures, as well as various surgical instruments and imaging solutions tailored for ear, nose, and throat specialists. By focusing on less invasive techniques, Entellus Medical aims to improve patient outcomes, reduce recovery times, and minimize complications such as pain and bleeding. The company's approach includes the FinESS Sinus Treatment, which remodels sinus passages using a micro endoscope and balloon catheter, allowing for procedures that can be performed under local anesthesia. Founded in 2006 and based in Plymouth, Minnesota, Entellus Medical operates as a subsidiary of Stryker Corporation, emphasizing collaboration with healthcare professionals to address unmet needs in the ENT field.

Xanodyne Pharmaceuticals, Inc. operates as an integrated specialty pharmaceutical company that offers developing and commercializing products in women’s healthcare and pain management in the United States.The company was formerly known as Xanodyne Pharmacal, Inc. and changed the name to Xanodyne Pharmaceuticals, Inc. in February, 2004. Xanodyne Pharmaceuticals, Inc. was incorporated in 2000 and is based in Newport, Kentucky.

QSpex Technologies, Inc. is an optical service center based in Alpharetta, Georgia, that specializes in producing high-quality finished eyewear in the United States. Founded in 2007, the company developed a patented method for manufacturing premium lenses directly in optical offices, allowing for a cost-effective and efficient process. Utilizing advanced touchless transfer technology, QSpex enables the quick fabrication of lenses, including single vision, progressive, anti-reflective, photochromic, and polar options, with lens treatments integrated during the production process. This innovative approach allows eyewear providers to deliver finished products to patients on the same day as their eye exams. However, the company filed for voluntary liquidation under Chapter 7 in June 2020.

Accumetrics is a privately-held company based in San Diego, California, that specializes in the development, manufacturing, and marketing of the VerifyNow System, which includes a comprehensive suite of assays for assessing platelet function. Founded in 1996, the company initially sold to Radiometer in 2000 but was repurchased by its management and investors in 2003. Accumetrics focuses on diagnostic instrumentation and test kits designed to measure individual responses to various antiplatelet agents, providing essential tools for healthcare professionals in the evaluation of platelet activity and ensuring effective patient treatment.

Complete Genomics specializes in high-quality, affordable DNA sequencing and analysis, facilitating large-scale research into the genetic mechanisms of drug responses and complex diseases. The company has developed a comprehensive genomics analysis platform that integrates proprietary human sequencing technology with advanced informatics and data management software. This approach ensures that customers receive ready-to-use data for genome-based research, supporting advancements in personalized medicine and broader genetic studies. By combining innovative technology with a unique market strategy, Complete Genomics aims to transform the landscape of DNA sequencing.

Oraya Therapeutics focuses on developing noninvasive, robotically controlled treatments for inflammatory and neovascular diseases of the eye. The company is currently testing its first application of the IRay system, which aims to provide innovative solutions for eye-related conditions. By leveraging advanced technology, Oraya Therapeutics seeks to improve patient outcomes and enhance the management of ocular diseases.

Chroma Therapeutics Ltd. is a biotechnology company based in Abingdon, United Kingdom, specializing in the discovery and development of novel small molecule drugs targeting cancer and inflammatory disorders. Founded in 2000, Chroma leverages chromatin biology and innovative cell accumulation techniques to create its product pipeline. Key products include Tosedostat, an oral aminopeptidase inhibitor; CHR-3996, an optimized histone deacetylase inhibitor designed for cancer treatment; and CHR-2845, focused on hematological malignancies. The company is recognized for its systematic assembly of intellectual property in chromatin biology and has established a strong network of academic collaborations to enhance its research and development efforts.

Victory Pharma, Inc. is a specialty pharmaceutical company focused on acquiring, marketing, and developing prescription medications specifically designed to treat pain and related conditions. The company targets healthcare professionals, including rheumatologists, orthopedists, pain specialists, and primary care physicians, providing them with effective therapeutic options for chronic pain management. In addition to marketing existing products, Victory Pharma is dedicated to developing novel treatments that not only address pain effectively but also aim to reduce the side effects commonly associated with traditional pain therapeutics.

NeoVista Inc is focused on developing medical technologies aimed at improving the treatment of wet age-related macular degeneration (AMD), a condition that affects over 5 million people globally and is a leading cause of blindness among individuals over the age of 50. The company is engaged in clinical studies to validate its innovative technology, which shows promise in enhancing patient care and alleviating the challenges posed by this debilitating condition for both patients and healthcare providers. Through its efforts, NeoVista aims to significantly impact the quality of life for those affected by wet AMD.

Symphogen specializes in the development of recombinant polyclonal antibodies (rpAb), a novel class of biopharmaceuticals aimed at treating and preventing serious human diseases, including infectious diseases and cancer. The company has created compositions of recombinant polyclonal antibodies for specific medical applications, such as the treatment of idiopathic thrombocytopenic purpura and the prevention of hemolytic disease in newborns. These innovations help mitigate adverse reactions from smallpox vaccinations and facilitate quicker treatment initiation for cancer patients, ultimately improving the chances of successful outcomes.

Catalyst Biosciences, Inc. is a clinical-stage biopharmaceutical company headquartered in South San Francisco, California. The company specializes in developing innovative treatments for hemophilia and other rare bleeding disorders, utilizing its engineered subcutaneous coagulation factors to promote blood clotting. This approach aims to address the inherent limitations of traditional intravenous treatments and improve patient outcomes. Catalyst's product portfolio includes Marzeptacog alfa (activated), an advanced coagulation Factor VIIa that has completed Phase II development for hemophilia A or B with inhibitors, and Dalcinonacog alfa, a next-generation Factor IX therapy that has finished Phase IIb clinical trials for hemophilia B. Additionally, the company is working on CB 2679d-GT, an early-stage gene therapy for hemophilia B, as well as other treatments targeting dry age-related macular degeneration and systemic complement inhibitors. Catalyst Biosciences has also formed strategic collaborations with Mosaic Biosciences and Biogen to enhance its research and development efforts in these therapeutic areas. The company was founded in 2002 and has a commitment to addressing unmet medical needs in coagulation and complement disorders.

Medlogics was founded upon principles of innovative, best in class solutions to local drug delivery. Accordingly, Medlogics is determined to provide safe, effective and clinically superior implantable devices to patients and their physicians, worldwide. Medlogics is focused on developing a next-generation drug eluting stent technology using a novel stent and drug delivery approach to treating coronary artery disease.

ROX Medical, Inc. is a medical device company based in San Clemente, California, specializing in interventional vascular therapy devices aimed at treating uncontrolled hypertension and chronic obstructive pulmonary disease (COPD). The company develops the ROX Coupler, which is designed to lower blood pressure in patients with treatment-resistant hypertension by reducing peripheral vascular resistance and enhancing vascular compliance. Additionally, the device aims to improve oxygen delivery to tissues in COPD patients, helping to alleviate symptoms and enhance exercise tolerance. Founded in 2003, ROX Medical focuses on innovative solutions that enhance patient well-being through advanced medical technology.

Nellix has developed an original device designed to address and expand the indication for the less invasive treatment of Abdominal Aortic Aneurysms (AAAs) and Thoratic Aortic Aneurysms (TAAs). Enabling the treatment of all aneurysms with a low profiles delivery system and innovative endograft, the Nellix device has the potential to double the market size for Endovascular Aneurysms Repair (EVAR), which exceeded $800M in 2008 with a 16% CAGR (Med Tech Insight).

Oraya Therapeutics focuses on developing noninvasive, robotically controlled treatments for inflammatory and neovascular diseases of the eye. The company is currently testing its first application of the IRay system, which aims to provide innovative solutions for eye-related conditions. By leveraging advanced technology, Oraya Therapeutics seeks to improve patient outcomes and enhance the management of ocular diseases.

ATS Medical, doing business as Medtronic ATS Medical, Inc., is a medical device manufacturer that specializes in products for cardiovascular surgery. Mechanical heart valves, aortic valve graft prostheses, and other cardiovascular accessories are available from the company. Medtronic ATS Medical markets and distributes its products to the healthcare industry worldwide. ATS Medical was acquired by Medtronic on August 12, 2010

Revance Therapeutics is a biotechnology company that focuses on developing, manufacturing, and commercializing neuromodulators for aesthetic and therapeutic applications. Its primary product, DaxibotulinumtoxinA for injection (DAXI), is undergoing various clinical trials for treating conditions such as glabellar lines, cervical dystonia, adult upper limb spasticity, and plantar fasciitis, while also being explored for chronic migraine treatment. Additionally, Revance is developing topical formulations of DAXI and a biosimilar to BOTOX. The company has established collaborations for the development and commercialization of these products. Revance also offers a portfolio of aesthetic products, including the RHA Collection of dermal fillers and the HintMD platform. Founded in 1999 and headquartered in Newark, California, Revance Therapeutics was previously known as Essentia Biosystems.

Corium International, Inc. is a biopharmaceutical company based in Menlo Park, California, that specializes in the development, manufacture, and commercialization of specialty pharmaceutical products utilizing transdermal and transmucosal delivery systems. The company offers a range of products, including the Clonidine Transdermal Delivery System for hypertension, Fentanyl TDS for chronic pain management, and Crest Whitestrips for teeth whitening. Corium's pipeline includes Twirla, a hormonal contraceptive patch; MicroCor hPTH(1-34) for severe osteoporosis; and transdermal systems for Alzheimer's treatment, among others. Additionally, the company is advancing projects for psychiatric disorders and Parkinson's disease. Corium collaborates with several pharmaceutical companies, enhancing its research and development capabilities. The firm is recognized for its proprietary delivery technologies that improve therapeutic outcomes and safety profiles across various therapeutic areas.

Orthovita is a company based in Malvern, Pennsylvania, specializing in the development and marketing of orthobiologic and biosurgery products. Its product offerings include medical implants designed for the fusion, regeneration, and fixation of human bones, alongside a biosurgery platform that provides solutions for controlling intra-operative bleeding, also referred to as hemostasis. Orthovita distributes its products directly and through a network of non-stocking distributors and independent sales agents in the United States, as well as through independent stocking distributors in international markets. The company has established strategic partnerships with various organizations to enhance its product offerings and market reach. Founded in 1992, Orthovita continues to be a key player in the spine and orthopedic biosurgery sectors.

Xanodyne Pharmaceuticals, Inc. operates as an integrated specialty pharmaceutical company that offers developing and commercializing products in women’s healthcare and pain management in the United States.The company was formerly known as Xanodyne Pharmacal, Inc. and changed the name to Xanodyne Pharmaceuticals, Inc. in February, 2004. Xanodyne Pharmaceuticals, Inc. was incorporated in 2000 and is based in Newport, Kentucky.

Horizon Therapeutics is a biopharmaceutical company based in Northbrook, Illinois, established in 2005. The company specializes in developing prescription drugs aimed at providing relief for mild to moderate pain and managing arthritis. Among its notable product candidates are HZT-501, a proprietary fixed-dose combination of a nonsteroidal anti-inflammatory drug (NSAID) and ibuprofen, and HZT-602, which is a combination oral medication that includes naproxen and famotidine.

Oraya Therapeutics focuses on developing noninvasive, robotically controlled treatments for inflammatory and neovascular diseases of the eye. The company is currently testing its first application of the IRay system, which aims to provide innovative solutions for eye-related conditions. By leveraging advanced technology, Oraya Therapeutics seeks to improve patient outcomes and enhance the management of ocular diseases.

Millennium Pharmacy Systems is a pharmacy services provider focused on the long-term care industry. Headquartered in Chicago, Illinois, the company offers a unique approach to pharmacy services by integrating Just-In-Time Dispensing with electronic prescription ordering, formulary management, and comprehensive medication administration. This combination enables nursing and assisted living communities to enhance patient care while effectively reducing costs and improving operational efficiency. Millennium's commitment to timely delivery and medication accuracy is reflected in its customer guarantees, supporting clients in meeting compliance requirements more easily.

MicroPort Scientific is a medical equipment manufacturer and distributor. The company's products include cardiovascular, orthopedic, cardiac rhythm management, electrophysiology, endovascular, neurovascular, and surgical robots.

StrataGent Life Sciences, Inc. is a specialty drug therapy company focused on creating painless and non-invasive alternatives to injectable therapies. The company's innovative products utilize proprietary microjet technology, which enables the delivery of both large and small therapeutic molecules without the need for devices to penetrate the skin. This approach aims to enhance patient comfort and compliance in medical treatments. StrataGent's commitment to advancing its technology was recognized in May 2004, when the company received a $2 million award from the Advanced Technology Program at the National Institute of Standards and Technology to further develop its microjet technology.

EUSA Pharma, founded in March 2006 and headquartered in the UK, is a profitable specialty pharmaceutical company that operates globally with a focus on oncology and other critical diseases. The company markets a portfolio of five approved specialty hospital products, including Caphosol®, Xenazine®, Collatamp®, Custodiol®, and Fomepizole®, along with several named-patient products. EUSA Pharma is dedicated to addressing rare diseases and conditions such as oral mucositis, a common side effect of cancer treatments. The company has submitted a Marketing Authorization Application for FOTIVDA (tivozanib HCL) as a first-line therapy for renal cell carcinoma. With plans to expand its portfolio through acquisitions and in-licensing, EUSA Pharma's operations extend across Europe and the USA, supported by a network of commercial partners in Europe, the Middle East, Asia, and Latin America, making its products available in approximately 40 countries worldwide. The company is led by an experienced management team with a strong track record in the specialty pharmaceutical sector.

Alaunos Therapeutics is a clinical-stage biotechnology company focused on developing innovative treatments for cancer, specifically through adoptive TCR-T cell therapy. The company utilizes a unique gene expression and control technology to deliver DNA that targets neoantigens derived from genomic mutations in solid tumors. This approach aims to enhance the immune response against cancer cells. Alaunos is currently conducting Phase 2 clinical studies to evaluate the efficacy of its therapies, including the immune system cytokine interleukin-12 for breast cancer and advanced melanoma. Additionally, the company is exploring multiple investigational new drug applications for new therapeutic targets, leveraging its advanced technology to improve treatment outcomes for patients.

Ception Therapeutics is a biopharmaceutical company dedicated to the discovery and development of innovative therapies for unmet medical needs. Founded by experienced pharmaceutical executives, the company is engaged in creating new drugs and treatments for challenging illnesses. Its product portfolio includes Reslizumab, which is aimed at treating eosinophilic inflammatory conditions, and a class of small molecule anti-TNF receptor agents that have the potential for oral administration. Additionally, Ception's offerings encompass treatments for central nervous system disorders, pain, and cancer, featuring eight proprietary products in the United States and over 100 products available internationally. The company's research pipeline focuses on developing new compounds and expanding indications for existing therapies.

Healthcare Brands International (HBI) is a new company helping to turn innovative medical product technology into successful consumer brands.

United Orthopedic Group is a global orthopedic company engaged in the manufacturing of non-invasive orthopedic rehabilitation products, including a range of orthopedic braces. The company focuses on providing high-quality solutions and complementary services aimed at enhancing clinical effectiveness and patient satisfaction. With a commitment to outstanding service for orthopedic physicians, United Orthopedic Group has established a reputation for quality and innovation. The company is also characterized by its rapid growth and strong financial backing, which supports an active acquisition strategy to expand its portfolio of partner companies.

NeoVista Inc is focused on developing medical technologies aimed at improving the treatment of wet age-related macular degeneration (AMD), a condition that affects over 5 million people globally and is a leading cause of blindness among individuals over the age of 50. The company is engaged in clinical studies to validate its innovative technology, which shows promise in enhancing patient care and alleviating the challenges posed by this debilitating condition for both patients and healthcare providers. Through its efforts, NeoVista aims to significantly impact the quality of life for those affected by wet AMD.

Prism Pharmaceuticals, Inc. is an acute care pharmaceutical company based in King of Prussia, Pennsylvania, founded in 2004. The company specializes in the development and commercialization of cardiovascular injectable products specifically for the United States market. Its notable offerings include NEXTERONE, an injectable antiarrhythmic agent, and PM103, an intravenous formulation of clopidogrel bisulfate.

Chroma Therapeutics Ltd. is a biotechnology company based in Abingdon, United Kingdom, specializing in the discovery and development of novel small molecule drugs targeting cancer and inflammatory disorders. Founded in 2000, Chroma leverages chromatin biology and innovative cell accumulation techniques to create its product pipeline. Key products include Tosedostat, an oral aminopeptidase inhibitor; CHR-3996, an optimized histone deacetylase inhibitor designed for cancer treatment; and CHR-2845, focused on hematological malignancies. The company is recognized for its systematic assembly of intellectual property in chromatin biology and has established a strong network of academic collaborations to enhance its research and development efforts.

Symphogen specializes in the development of recombinant polyclonal antibodies (rpAb), a novel class of biopharmaceuticals aimed at treating and preventing serious human diseases, including infectious diseases and cancer. The company has created compositions of recombinant polyclonal antibodies for specific medical applications, such as the treatment of idiopathic thrombocytopenic purpura and the prevention of hemolytic disease in newborns. These innovations help mitigate adverse reactions from smallpox vaccinations and facilitate quicker treatment initiation for cancer patients, ultimately improving the chances of successful outcomes.

Breg, Inc. is a manufacturer that specializes in sports medicine products aimed at improving orthopedic patient care. The company offers a diverse range of products, including knee braces, cold therapy devices, and various bracing solutions for the hip, shoulder, elbow, wrist, spine, and foot. Additionally, Breg provides DVT prophylaxis products, canes, crutches, walkers, home therapy kits, and pediatric items. The company also features Breg Vision, a workflow management software designed to streamline patient care. Established in 1989 and headquartered in Carlsbad, California, Breg operates in both the United States and Mexico, distributing its products through a network of distributors domestically and internationally.

Touchstone Health is a New York-based Medicare Advantage insurer that provides a range of healthcare services aimed at seniors and Medicare beneficiaries. The company specializes in offering zero and low-cost Medicare health insurance plans, which include various benefits such as medical, pharmacy, dental, and mental health services. Additionally, Touchstone Health focuses on promoting healthy living and education through its member care programs and Medicare savings initiatives. The organization also provides value-added services in areas like dental, hearing, and vision, ensuring that patients can select the most suitable Medicare Advantage plan tailored to their individual needs.

Light Sciences Oncology, Inc. is focused on developing and manufacturing talaporfin sodium, a water-soluble drug designed for the treatment of solid tumors. The company offers a single-use disposable device that employs LED technology to provide a fixed light dose, enhancing the effectiveness of the drug. Talaporfin sodium is utilized in treating various conditions, including hepatocellular carcinoma, metastatic colorectal cancer, and benign prostatic hyperplasia. Founded in 1994, Light Sciences Oncology is headquartered in Bellevue, Washington, and also engages in research and development services for oncology drugs.

Light Sciences Oncology, Inc. is focused on developing and manufacturing talaporfin sodium, a water-soluble drug designed for the treatment of solid tumors. The company offers a single-use disposable device that employs LED technology to provide a fixed light dose, enhancing the effectiveness of the drug. Talaporfin sodium is utilized in treating various conditions, including hepatocellular carcinoma, metastatic colorectal cancer, and benign prostatic hyperplasia. Founded in 1994, Light Sciences Oncology is headquartered in Bellevue, Washington, and also engages in research and development services for oncology drugs.

Receptor BioLogix is a biotechnology company based in Palo Alto, California, focused on developing receptor-based biological therapeutics for the treatment of cancer, inflammatory, and autoimmune diseases. The company has created Hermodulins, which are pan-HER ligand traps designed to inhibit feedback mechanisms that can reduce the effectiveness of various cancer therapies. These innovations have shown anti-cancer potential in preclinical studies. Additionally, Receptor BioLogix is advancing its Intron Fusion Protein platform, which aims to discover novel splice variants of human proteins that may possess therapeutic potential.

BENU, Inc. is an innovator in software technology for payroll, benefits and human resources. The company's newest platform, syncHR, reinvents the management of HR, benefits and payroll with its single application and single database. SyncHR's event-driven software provides real-time transactions, reduces administrative effort, increases data quality, and provides a seamless user experience.